A carregar...
EXTH-05. miR-34a INHIBITS GLIOBLASTOMA CELL PROLIFERATION AND SENSITIZES TO TEMOZOLOMIDE
Glioblastoma (GBM) is the most common primary brain tumor with a median survival of 14.5 months, despite maximal therapy consisting of surgical resection, radiation and temozolomide (TMZ). Genetic profiling has shown an average of three driver mutations localized to the p53, Rb and receptor tyrosine...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5691989/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.301 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|